Filing: US CBP decides, regarding the Masimo patent fight, that Apple can avoid a ban and sell the Apple Watch Series 9 if pulse oximetry features are disabled
The U.S. Customs agency has handed down its decision on whether Apple's proposed redesign of the Apple Watch Series 9 …
Context & Ripple Effects
The decision follows an ITC import remedy that the Biden administration declined to veto, while Apple had reportedly been pursuing a software-based workaround rather than a hardware redesign. It creates a path through the dispute by separating the watch's saleability from one contested sensing capability.
The later record shows the boundary remained contested: Masimo subsequently challenged CBP's authority over an advice ruling involving blood-oxygen functionality. That makes this an important early test of how much discretion border enforcement has over product redesigns.
First-order effects
- Apple can import and sell the affected Apple Watch Series 9 configuration in the US with pulse-oximetry disabled, avoiding an immediate product-level exclusion for that version.
- Masimo's exclusion remedy does not block that redesigned configuration, though its underlying patent dispute and leverage over the contested feature remain intact.
Second-order effects
- Consumers and retailers retain access to the watch, but product differentiation shifts because a health-sensing function is unavailable in the compliant US configuration.
- The ruling gives other connected-device makers a concrete incentive to assess whether disputed sensor features can be isolated or disabled rather than requiring an entire device to be withdrawn.
Third-order effects
- If this approach is sustained, patent import remedies may increasingly produce market-specific feature configurations, with software controls becoming part of product-compliance strategy for sensor-equipped devices.
- Disputes over whether a redesign falls outside an exclusion order could make CBP's technical determinations a more consequential battleground alongside ITC and court proceedings.
The trend: Connected-health hardware is increasingly being governed as a bundle of separable sensing features, allowing legal and trade remedies to reshape software availability rather than simply remove devices from shelves.